[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-steatoses\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-steatoses":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,79,99,126,155],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100507233","preoperative-ketogenic-diet-for-reduction-of-hepatic-steatosis-100507233",false,"NCT05884723","Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis","Implementation of a Preoperative Ketogenic Diet for Reduction of Hepatic Steatosis Prior to Hepatectomy: a Randomized Control Trial","Inclusion Criteria:\n\n* Patients 18 years of age or older undergoing any type of liver resection (e.g. wedge, formal hepatectomy), either open or laparoscopic, for colorectal liver metastases (CRLM)\n* Patients with evidence of hepatic steatosis on pre-operative imaging (CT or MR) or biopsy.\n* Ability to use an app based nutritional program to track macronutrient uptake throughout the dietary intervention.\n\nExclusion Criteria:\n\n* Patients undergoing liver resection for any other indication\n* Patients on sodium glucose co-transporter 2 (SGLT-2) inhibitors (these are contraindicated with a ketogenic diet).\n* Patients without evidence of hepatic steatosis.\n* Patients with evidence of liver fibrosis or cirrhosis on preoperative bloodwork or imaging.\n* Patients with alcohol-related hepatic steatosis.\n* Patients with a known bleeding disorder.","ALL","18 Years",{"count":19,"type":20},124,"ESTIMATED","INTERVENTIONAL",[23],"NA","Non-alcoholic fatty liver disease is becoming increasingly common in Canada and throughout the world. Fatty liver can increase the risks of perioperative complications for those who need liver surgery. A ketogenic diet is low in carbohydrates and can be very effective in reducing liver fat content. The purpose of this randomized control trial is to compare the effect of a short duration (4 week) preoperative ketogenic diet on operative and disease outcomes in patients undergoing liver surgery. One arm will be randomized to the ketogenic diet and the other will receive standard of care pre-operative dietary consultation.",[26,27,28],"Liver Steatoses","Liver Metastasis Colon Cancer","NAFLD",[30,28,31],"ketogenic diet","colorectal liver metastases","RECRUITING","2026-05-15",{"date":35,"type":36},"2026-05-19","ACTUAL",{"date":38,"type":36},"2024-05-01",{"date":40,"type":20},"2032-12",{"name":42,"class":43},"Anton Skaro","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":62,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100629537","prevalence-and-risk-factors-of-metabolic-associated-hepatic-steatosis-in-individuals-living-with-type-1-diabetes-100629537","NCT07475962","Prevalence and Risk Factors of Metabolic-Associated Hepatic Steatosis in Individuals Living With Type 1 Diabetes","STEA-DT1","Inclusion Criteria:\n\n* Individuals ≥ 18 years of age.\n* A clinical diagnosis of type 1 diabetes or Latent Autoimmune Diabetes in Adults (LADA) for at least one year, as per the investigators' clinical judgment (confirmatory C-peptide and antibodies will not be required).\n\nExclusion Criteria:\n\n* Alcohol consumption exceeding 20g per day in women or 30g per day in men.\n* Known chronic liver disease (including viral, drug-induced, Wilson disease, deficit in alpha-1-antirypsin, hemochromatosis, autoimmune hepatitis, etc.).\n* Evidence of cirrhosis based on a result of liver biopsy, or history of portal hypertension presented by ascites, hepatic encephalopathy or varices.\n* History of use of medications known to induce liver steatosis, including corticosteroids, high-dose estrogens, tamoxifen, methotrexate, amiodarone, or tetracycline.\n* Ongoing pregnancy.\n* Life expectancy of less than 5 years, as per investigators' clinical judgment.",{"count":53,"type":20},100,"3 Days","OBSERVATIONAL","The goal of this observational cross-sectional study is to assess the prevalence and stage of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), specifically liver steatosis and fibrosis in adults aged 18 and older living with type 1 diabetes or Latent Autoimmune Diabetes in Adults (LADA) in Quebec.\n\nThe main questions it aims to answer are:\n\n1. What is the prevalence and severity of liver steatosis and fibrosis among people living with type 1 diabetes in Québec?\n2. Are there patients with type 1 diabetes who have advanced, undiagnosed stages of liver disease that require management but are missed by current standard care practices?\n\nResearchers will compare three participant subgroups based on adiposity (a control group without increased adiposity, an overweight group with increased adiposity, and an obesity group with increased adiposity) to see if the prevalence and severity of hepatic steatosis and fibrosis are highest in the obesity group and lowest in the control group. They will also explore if variables and potential risk factors associated with liver disease differ across these subgroups.\n\nParticipants will attend a single study visit where they will be asked to:\n\n* Provide clinical data through laboratory analyses.\n* Undergo specific clinical procedures.\n* Complete validated questionnaires.",[58,26,59,60,61],"Type 1 Diabetes","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Liver Fibrosis","Latent Autoimmune Diabetes in Adult (LADA)",[63,64,65,66,67,68],"MASLD","Liver steatosis","Liver fibrosis","LADA","Body composition","Type 1 diabetes","NOT_YET_RECRUITING","2026-03-19",{"date":72,"type":36},"2026-03-23",{"date":74,"type":20},"2026-04-01",{"date":76,"type":20},"2027-05-30",{"name":78,"class":43},"Institut de Recherches Cliniques de Montreal",{"id":80,"slug":4,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":16,"minAge":17,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":44},"100327397","NCT03542578","Diagnosis of Fatty Liver With Outpatient Ultrasound","Inclusion Criteria:\n\n* all patients presenting to dedicated clinic\n\nExclusion Criteria:\n\n* presence of ascites, inability to give consent to have study",true,"80 Years",{"count":87,"type":20},500,"This study will evaluate whether ultrasound performed during outpatient visit is effective in early diagnosis of fatty liver.",[26],"2026-03-08",{"date":92,"type":36},"2026-03-11",{"date":94,"type":36},"2018-09-12",{"date":96,"type":20},"2026-12-30",{"name":98,"class":43},"Medical College of Wisconsin",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":5},"100339417","china-health-big-data-100339417","NCT03699228","China Health Big Data","China Nationwide Multi Center Big Data Study on the Quantitative Computed Tomography (QCT) and Health Status of Check -up Population","China biobank","Inclusion Criteria:\n\nhealth check subjects 30-90 years old low dose chest CT scan\n\nExclusion Criteria:\n\npregnant women metal implant in the CT scan area","30 Years","90 Years",{"count":110,"type":20},30000,"In this nationwide multi center study the investigators combine the low dose chest CT scan data with QCT technology, to measure the BMD of spine, VAT and liver fat in the health check subjects. The aim of this study is to evaluate the performance of QCT in the health check field, and further to evaluate the prevalence of osteoporosis, obesity and liver steatosis in health check population across China.",[113,114,26],"Osteoporosis","Obesity",[116],"Bone mineral density, quantitative computed tomography, Osteoporosis, obesity, liver steatosis","2025-08-13",{"date":119,"type":36},"2025-08-17",{"date":121,"type":36},"2017-12-01",{"date":123,"type":20},"2026-12-31",{"name":125,"class":43},"Beijing Jishuitan Hospital",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100602376","evaluation-of-non-invasive-tests-for-metabolic-liver-disease-100602376","NCT07122700","Evaluation of Non-Invasive Tests for Metabolic Liver Disease","Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) Study 2.0 - An FNIH Biomarkers Consortium Study","NIMBLE","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged \\> 18 years and \\\u003C 75 years\n4. Participants must exhibit some manifestations of metabolic dysregulation. Either:\n\nA. Physician-diagnosed T2DM for at least 90 days with HbA1c \\> 6.5 and antidiabetic therapy, if any, stable for at least 90 days prior to screening or B. At least any one of the following six metabolic syndrome criteria \\[6\\]\n\n1\\. body mass index (BMI) of \\> 25 kg\u002Fm2 2. waist circumference: i. \\> 102 cm for men ii. \\> 88.9 cm for women 3. fasting triglyceride concentration \\> 150 mg\u002FdL i. or ongoing treatment with triglyceride lowering medication 4. HDL-cholesterol concentration: i. \\\u003C 40 mg\u002FdL for men ii. \\\u003C 50 mg\u002FdL for women iii. or ongoing treatment with cholesterol lowering medication. 5. fasting glucose concentration \\> 100 mg\u002FdL 6. either semi-recumbent or supine blood pressure systolic \\> 130 mmHg and\u002F or diastolic \\> 85 mmHg i. or ongoing treatment with antihypertensive medication. 5. FIB-4 \\> 1.3 (age \\\u003C 65 years) and \\> 2.0 (age \\> 65 years) 6. Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration\n\nExclusion Criteria:\n\n1. Known history or evidence of other forms of chronic liver disease other than MASLD\u002FMASH including but not limited to viral hepatitis B or C, autoimmune liver disease, primary biliary cholangitis, primary sclerosing cholangitis, Wilson disease, hemochromatosis, drug-induced liver disease, conditions involving bile duct obstructions, liver cancer, past history of HCC or HCC treatment, listed for or history of liver transplantation, prior resection of liver, etc.\n2. Current or past evidence of decompensated liver disease defined by overt ascites that is clinically obvious and requires diuretic therapy, overt encephalopathy requiring therapy or history of variceal hemorrhage\n3. Circulating Alanine aminotransferase (ALT)\\> 5xULN\n4. Ongoing or recent (within the last two years prior to screening) consumption of significantly greater than moderate amounts of alcohol.\n\n   * A standard alcoholic drink is any drink that contains about 14 g of pure alcohol, such as 12 fluid ounces of regular beer 8-10 fluid ounces of malt liquor or flavored malt beverages such as hard seltzer 5 fluid ounces of table wine 3-4 fluid ounces of fortified wine such as sherry or port 2-3 fluid ounces of cordial liqueur or aperitif 1.5 fluid ounces (a single jigger or shot) of brandy, cognac, or distilled spirits such as gin, rum, tequila, vodka, whiskey, etc.\n   * Significantly greater than moderate alcohol consumption is defined as on average over a 2-year period prior to screening:\n\n   Women\n   * \\>1 standard drink per day and\u002For\n   * \\>14 standard drinks per week Men\n   * \\>2 standard drinks per day and\u002For\n   * \\>21 standard drinks per week in men\n\n     * An Alcohol Use Disorders Identification Test (AUDIT) score of 7 or higher\n     * A PEth test score of ≥ 20ng\u002Fml.\n5. In the opinion of the investigator, any contraindications to liver biopsy including but not limited to having significant uncorrected coagulopathy or thrombocytopenia, on chronic anticoagulation with Direct Oral Anticoagulants (DOACs), or on low dose heparin or Warfarin.\n6. Uncontrolled systolic blood pressure \\> 180 mmHg and diastolic blood pressure \\> 120 mmHg at screening. Blood pressure will be obtained after at least 10 minutes of resting in a semi-recumbent or supine position.\n7. Any systemic disease that in the opinion of the investigator precludes inclusion of the patient in the trial\n8. Unable or unwilling to provide informed consent\n9. Unwilling to undergo liver biopsy procedure\n10. Unable or unwilling to comply with requirements for study procedures (such as fasting)\n11. Unable to perform study procedures in the opinion of the investigator\n12. Participants who are unwilling or unable (e.g. due active implants such as pacemaker or having a waist diameter (calculated as: diameter = circumference \u002F π) 70cm, unless a wide-bore MRI machine is available) to undergo MRI procedures.\n13. Pregnancy or planned pregnancy within 4 months of screening.\n14. Participation in another clinical trial within 30 days, or dosing with an investigational agent within 90 days prior to signing the ICF for this study.","75 Years",{"count":136,"type":20},400,"The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). MASH is characterized by liver inflammation accompanied by simultaneous fat accumulation in the liver.",[139,140,141,142,60,143,26,144],"Metabolic Associated Fatty Liver Disease","Metabolic Associated Steatotic Liver Disease","Cirrhosis, Liver","NASH","Liver Fat","Liver Inflammation","2025-08-07",{"date":147,"type":36},"2025-08-14",{"date":149,"type":36},"2025-05-13",{"date":151,"type":20},"2026-07-31",{"name":153,"class":43},"Foundation for the National Institutes of Health",4,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":162,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":21,"phases":166,"briefSummary":169,"conditions":170,"keywords":177,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":44},"100597053","phase-1-crispr-edited-hla-donor-liver-transplant-to-reduce-rejection-100597053","NCT07053488","CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection","A Phase 1\u002F2, Open-Label, Single-Arm Study to Evaluate the Safety, Immunogenicity Reduction, Transplant Function, and Feasibility of Ex Vivo CRISPR-Cas9 Gene-Edited Donor Liver Transplantation Targeting HLA Class I (HLA-A, HLA-B) and Class II (Via CIITA) Genes.","Inclusion Criteria:\n\n* Adults aged 16-85 (inclusive) with end-stage liver disease or acute liver failure who are eligible for liver transplantation.\n* Require a liver transplant and have been allocated a donor liver graft (from a deceased donor) that will be used in the study after gene editing.\n* No immediately available fully HLA-matched donor (since the study targets patients who would otherwise receive an HLA-mismatched organ; standard allocation generally does not consider HLA matching for liver, so most patients will qualify).\n* Medically suitable for transplant surgery and able to tolerate standard immunosuppressive therapy (no contraindications to transplant such as uncontrolled infection or other active serious disease that would preclude surgery).\n* Informed Consent: Able to understand the investigational nature of the trial and provide written informed consent. Patients (and their legal representatives if applicable) must consent to the use of a genetically modified organ and to long-term follow-up including multiple biopsies and immune monitoring.\n* Willingness to comply with all study procedures and availability for the duration of follow-up (including frequent monitoring visits).\n\nExclusion Criteria:\n\n* Active uncontrolled infection (e.g., sepsis, active tuberculosis) that would severely increase transplant risk or confound interpretation of immune-related outcomes.\n* Uncontrolled HIV or chronic viral infections that are not well-managed. (Note: Patients with hepatitis B or C may be included if adequately treated or under control, as these are common in liver failure, but such patients should not have active, replicating virus at transplant if possible.)\n* Multi-organ transplant requirement: Patients needing more than a liver alone (e.g., liver-kidney dual transplant) are excluded, as the trial is only evaluating single organ (liver) outcomes.\n* Pregnancy or breastfeeding: Female participants of childbearing potential must have a negative pregnancy test prior to transplant and must agree to use effective contraception. The effects of a gene-edited organ transplant on a fetus\u002Finfant are unknown, and immunosuppressive drugs can also harm a pregnancy.\n* Severe concurrent illness not related to liver disease that would limit survival to \\\u003C1 year or make the patient an unsuitable candidate (e.g., advanced heart failure, uncontrolled diabetes with complications, etc.).\n* Allergy or hypersensitivity to study-related products: If any components used in the ex vivo gene editing (such as a specific vehicle or enzyme) have known severe allergies in the recipient, they will be excluded. (For instance, although unlikely, if a patient had a documented severe immune reaction to Streptococcus pyogenes Cas9 or similar proteins, they would not be enrolled.)\n* Inability to follow the protocol or comply with follow-up: this includes psychiatric, social or logistical factors that would prevent adhering to the intense monitoring schedule (for example, lack of reliable transportation or support).","16 Years","85 Years",{"count":165,"type":20},90,[167,168],"PHASE1","PHASE2","This early-phase clinical trial will assess the use of ex vivo CRISPR-Cas9 genome editing on donor liver grafts to reduce immunogenicity before transplantation. Donor livers will have HLA-A and HLA-B genes knocked out, and HLA class II expression disabled (by targeting the CIITA transactivator gene), aiming to create a \"hypoimmunogenic\" organ less prone to rejection. The edited liver is then transplanted into patients with end-stage liver disease. The primary focus is on safety and feasibility - determining whether a CRISPR-edited liver can be transplanted successfully and function normally - as well as evaluating reductions in immune response (acute rejection, anti-donor T cell activation) and graft function over time.",[171,172,173,174,175,176,26],"Liver Diseases","Liver Cancer","Liver Cirrhosis","Liver Failure","Liver Metastases","Liver Transplant Rejection",[178,179,180,181,182,183,184,185,186,187,188],"End-Stage Liver Disease requiring transplantation","Prevention of Allograft Rejection in Liver Transplantation","CRISPR-Cas9","Gene Editing","Liver Transplant","Organ Transplantation","Immunogenicity Reduction","HLA Knockout","Hypoimmunogenic Graft","Allograft Rejection","Universal Donor Organ","2025-06-26",{"date":191,"type":36},"2025-07-08",{"date":193,"type":36},"2025-06-01",{"date":195,"type":20},"2028-12-28",{"name":197,"class":43},"AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC"]